| Market Capitalization (Millions $) |
61 |
| Shares
Outstanding (Millions) |
30 |
| Employees |
12 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-58 |
| Cash Flow (TTM) (Millions $) |
-23 |
| Capital Exp. (TTM) (Millions $) |
0 |
Immuneering Corporation
Immuneering Corp is a biotechnology company that specializes in developing computational tools for drug discovery and precision medicine. It was founded in 2008 by Ben Zeskind and Harvard professor Mark Namchuk in Cambridge, Massachusetts.
The companyes main focus is to develop technology that can help identify new therapeutic targets and optimize drug development processes. The technology works by integrating vast amounts of data from various sources, including genomic, proteomic, and clinical data, to create a comprehensive understanding of disease biology.
Immuneering Corpes platform is built on proprietary algorithms and machine learning techniques that can analyze large and complex datasets. They use these tools to identify patterns and relationships that can help uncover the underlying mechanisms of disease and identify new drug targets.
The companyes technology is applicable across a wide range of therapeutic areas, including oncology, immunology, neurodegenerative diseases, and infectious diseases. Its clients include leading pharmaceutical and biotechnology companies as well as academic research institutions.
One of Immuneering Corpes unique offerings is their ability to identify mechanisms of drug resistance, which is a major challenge in drug development. They use their technology to analyze large patient datasets to identify why some patients do not respond to certain drugs, and use this information to identify new drug targets or optimize treatment regimens.
As of 2021, Immuneering Corp has raised over $117 million in funding from investors such as Omega Funds, Boxer Capital, and MiraeAsset. The company has also formed several strategic partnerships with leading pharmaceutical companies, including AbbVie and Sanofi.
Company Address: 245 Main St Cambridge 2142 MA
Company Phone Number: 500-8080 Stock Exchange / Ticker: NASDAQ IMRX
|
